Prothena Corp PLC (FRA:0PT)

€ 13.1 -1.2 (-8.39%) Market Cap: 710.61 Mil Enterprise Value: 220.07 Mil PE Ratio: 0 PB Ratio: 1.38 GF Score: 64/100

Q4 2023 Prothena Corporation PLC Earnings Call Transcript
Feb 15, 2024

€26.4 (+5.60%)

Earnings
Prothena Corporation PLC at Morgan Stanley Global Healthcare Conference Transcript
Sep 11, 2023
Prothena Corporation PLC at Jefferies Healthcare Conference Transcript
Jun 08, 2023
Prothena Corporation PLC at Bank of America Global Healthcare Conference Transcript
May 09, 2023
Prothena Corporation PLC at Stifel CNS Days (Virtual) Transcript
Mar 28, 2023
Q4 2022 Prothena Corporation PLC Earnings Call Transcript
Feb 23, 2023

€47.6 (-1.51%)

Earnings
Prothena Corporation PLC at Morgan Stanley Global Healthcare Conference Transcript
Sep 13, 2022
Prothena Corporation PLC at Bank of America Healthcare Conference Transcript
May 10, 2022
Prothena Corporation PLC at Stifel CNS Days (Virtual) Transcript
Mar 28, 2022
Q4 2021 Prothena Corporation PLC Earnings Call Transcript
Feb 17, 2022

€31.6 (-3.07%)

Earnings
Prothena Corporation PLC at Cantor Fitzgerald Global Healthcare Conference (Virtual) Transcript
Sep 27, 2021
Prothena Corporation PLC at Citi BioPharma Conference (Virtual) - Fireside Chat Transcript
Sep 08, 2021
Prothena Corporation PLC at RBC Capital Markets Global Healthcare Conference (Virtual) Transcript
May 19, 2021
Prothena Corporation PLC to Review Oral Presentations from AD/PD 2021 Transcript
Mar 11, 2021
Q4 2020 Prothena Corporation PLC Earnings Call Transcript
Feb 11, 2021

€12.7 (+1.60%)

Earnings
Prothena Corporation PLC to Discuss AFFIRM-AL Study - Conference Call Transcript
Feb 02, 2021
Prothena Corporation PLC - PRX004 Phase 1 Study Results Transcript
Dec 09, 2020
Prothena Corporation PLC to Discuss Results from Part 1 of the Phase 2 PASADENA Study - Conference Call Transcript
Sep 15, 2020
Q4 2019 Prothena Corporation PLC Earnings Call Transcript
Feb 12, 2020

€12.3 (+4.24%)

Earnings
Prothena Corporation PLC to Discuss Results of the Phase 3 VITAL Amyloidosis Study - Conference Call Transcript
Apr 18, 2019
Prothena Corporation PLC at Barclays Global Healthcare Conference Transcript
Mar 12, 2019
Q4 2018 Prothena Corporation PLC Earnings Call Transcript
Feb 14, 2019

€11 (-1.79%)

Earnings

Prothena Corporation PLC to Discuss AFFIRM-AL Study - Conference Call Transcript

Feb 02, 2021 / 01:00PM GMT

Release Date Price: €11.5 (+26.37%)

Transcript 8-K

Operator

Ladies and gentlemen, thank you for standing by, and welcome to Prothena's AFFIRM-AL study conference call. (Operator Instructions) Please be advised that today's conference is being recorded. (Operator Instructions)

I would now like to hand the conference over to your speaker today, Ms. Ellen Rose, Prothena's Head of Communications. Please go ahead, ma'am.

Ellen Rose

Prothena Corporation plc - Head of Communications

Thank you, operator. Hello, everyone, and welcome to Prothena's investor conference call to review the announcement regarding birtamimab and the confirmatory Phase III AFFIRM-AL study in Mayo Stage IV patients with AL amyloidosis. Please review the press release we issued on Monday afternoon, which is available on our website at prothena.com.

On today's call, Dr. Gene Kinney, our President and Chief Executive Officer, will provide introductory remarks about birtamimab and the series of activities that has led to initiating the AFFIRM-AL study. Dr. Wagner Zago, our Chief Scientific Officer, will speak about the underlying

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.